ISODIOL INTERNATIONAL INC. ANNOUNCES DISTRIBUTION AGREEMENT FOR SOUTH AMERICA
30 Agosto 2017 - 5:00AM
InvestorsHub NewsWire
August
30th, 2017 -- Vancouver, BC -- InvestorsHub NewsWire
-- Isodiol International
Inc. (CSE: ISOL)
(OTC:
LAGBF)
(FSE:
LB6A.F)
(the “Company” or
“Isodiol”) a
global cannabinoid innovator specializing in the development of
pharmaceutical and consumer products announces it has signed a
distribution partnership with FarmaUSA™, a leading global wholesale
distributor of imported pharmaceutical products in South America.
This is the latest action taken by the Company to further secure
its position in the Brazilian market and provide for an additional
expansion into greater South America.
This deal will expand Isodiol's product Isoderm™
in Brazil and across South America by utilizing
FarmaUSA's existing distribution and doctor network to
increase the presence of Isoderm™ Direct Effect
Technologies™. FarmaUSA will facilitate physician conferences
across the country to further educate healthcare professionals on
the benefits of Isoderm™ while continuing to work with regulatory
officials at Agência Nacional de Vigilância Sanitária (ANVISA) for
commencing a clinical trial.
Marcos Agramont, CEO of Isodiol International
Inc. stated, “This is a major milestone in the development of our
international expansion strategy. FarmaUSA is very well
respected among healthcare professionals in South America to help
facilitate this process for the Company. I anticipate a
dramatic increase in the amount of prescriptions being written by
physicians in these markets as we move forward and head towards a
clinical trial in the coming months.”
Djalma Nogueria, CEO of FarmaUSA stated, “We are
very excited to work with Isodiol in bringing Isoderm™ to the South
American market. We have seen a tremendous initial response
from the health professionals who have commenced prescribing the
product and we anticipate this to continue. With our Isodiol
partnership now established, we are well positioned to enter
additional markets in South America and become the leader in the
space.”
About Isodiol International
Inc.
Isodiol International
Inc. is
the market leader in pharmaceutical and nutraceutical grade
phytochemical compounds and the industry leader in the
manufacturing and development of phytoceutical consumer
products.
Isodiol is the pioneer of many firsts for the
cannabis industry including commercialization of a 99%+ pure
pharmaceutical grade cannabinoid crystalline isolate derived from
exempt parts of the hemp plant, micro-encapsulations, and
nanotechnology for the highest quality consumable and topical skin
care products.
Isodiol's growth strategy includes the
development of over-the-counter and pharmaceutical drugs, expanding
its phytoceutical portfolio and will aggressively continue
International expansion into Latin America, Asia and
Europe.
ON BEHALF OF
THE BOARD : “Marcos
Agramont” CEO & Director
CORPORATE
MEDIA: ir@isodiol.com www.isodiol.com
Join Us On
Face Book: https://www.facebook.com/isodiol/
Twitter: @isodiol
Forward-Looking
Information: This news release contains "forward-looking
information" within the meaning of applicable securities laws
relating to statements regarding the Company's business, products
and future the Company’s business, its product offerings and plans
for sales and marketing. Although the Company believes that the
expectations reflected in the forward looking information are
reasonable, there can be no assurance that such expectations will
prove to be correct. Readers are cautioned to not place undue
reliance on forward-looking information. Such forward looking
statements are subject to risks and uncertainties that may cause
actual results, performance and developments to differ materially
from those contemplated by these statements depending on, among
other things, the risks that the Company's products and plan will
vary from those stated in this news release and the Company may not
be able to carry out its business plans as expected. Except as
required by law, the Company expressly disclaims any obligation,
and does not intend, to update any forward looking statements or
forward-looking information in this news release. Although the
Company believes that the expectations reflected in the forward
looking information are reasonable, there can be no assurance that
such expectations will prove to be correct and makes no reference
to profitability based on sales reported. The statements in this
news release are made as of the date of this
release.
The CSE has not reviewed, approved or
disapproved the content of this press
release.
Isodiol (CE) (USOTC:ISOLF)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Isodiol (CE) (USOTC:ISOLF)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
Real-Time news about Isodiol International Inc (CE) (OTCMarkets): 0 recent articles
Más de Isodiol International Inc. (PC) Artículos de Noticias